Total submissions: 22
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Institute of Immunology and Genetics Kaiserslautern | RCV000047162 | SCV006076291 | likely pathogenic | Cystic fibrosis | 2025-04-25 | criteria provided, single submitter | clinical testing | ACMG Criteria: PVS1_S, PM2_P, PM3, PP5; Variant was found in heterozygous state. The patient was an asymptomatic carrier. |
| Fulgent Genetics, |
RCV005031525 | SCV005673278 | likely pathogenic | Bronchiectasis with or without elevated sweat chloride 1; Cystic fibrosis; Hereditary pancreatitis; Congenital bilateral aplasia of vas deferens from CFTR mutation | 2024-05-15 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV003474605 | SCV004213263 | likely pathogenic | Bronchiectasis with or without elevated sweat chloride 1 | 2024-03-28 | criteria provided, single submitter | clinical testing | |
| Institute of Human Genetics, |
RCV000047162 | SCV004100705 | pathogenic | Cystic fibrosis | 2024-05-22 | criteria provided, single submitter | clinical testing | Criteria applied: PS3_VSTR,PM3,PP4 |
| Eurofins- |
RCV002255273 | SCV003935049 | likely pathogenic | Hereditary pancreatitis | 2022-10-20 | criteria provided, single submitter | clinical testing | |
| MGZ Medical Genetics Center | RCV000047162 | SCV002580609 | likely pathogenic | Cystic fibrosis | 2022-01-13 | criteria provided, single submitter | clinical testing | |
| Sema4, |
RCV002255273 | SCV002529736 | uncertain significance | Hereditary pancreatitis | 2021-04-21 | criteria provided, single submitter | curation | |
| Genome- |
RCV000047162 | SCV001822004 | likely pathogenic | Cystic fibrosis | 2021-07-22 | criteria provided, single submitter | clinical testing | |
| Johns Hopkins Genomics, |
RCV000047162 | SCV001371813 | likely pathogenic | Cystic fibrosis | 2020-01-29 | criteria provided, single submitter | clinical testing | CFTR variant associated with variable clinical consequences. See www.CFTR2.org for phenotype information. |
| Ambry Genetics | RCV000047162 | SCV001185048 | uncertain significance | Cystic fibrosis | 2025-01-14 | criteria provided, single submitter | clinical testing | The c.489+3A>G intronic variant results from an A to G substitution 3 nucleotides after coding exon 4 in the CFTR gene. This variant (reported as 621+3A>G) was described in four Greek individuals with severe cystic fibrosis (CF), each with a second pathogenic mutation; however, the phase of these alterations is uncertain (Tzetis M et al. Hum Genet, 2001 Dec;109:592-601). In addition, this variant has been reported with a second pathogenic variant in other individuals with intermediate sweat chloride levels (Forzan M et al. J Hum Genet, 2010 Jan;55:23-6; Sermet-Gaudelus I et al. Thorax, 2010 Jun;65:539-44; Esposito MV et al. J Clin Med, 2020 Nov;9:). However, it has also been detected in trans with a pathogenic variant in multiple individuals with normal sweat chloride levels (Ambry internal data). Functional studies using RNA from patients and minigene assay showed that this variant results in partial and full exon skipping (Tzetis M et al. Hum Genet, 2001 Dec;109:592-601; Forzan M et al. J Hum Genet, 2010 Jan;55:23-6). In another RNA study, this variant has approximately 90% of wild type quantity and function (The Clinical and Functional TRanslation of CFTR (CFTR2) database available at http://cftr2.org. Accessed 12/15/2023). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on available evidence to date, this variant is unlikely to be causative of classic cystic fibrosis; however, its contribution to the development of a CFTR-related disorder is uncertain. This alteration is thus classified as a variant of unknown significance. |
| CFTR- |
RCV001009491 | SCV001169586 | pathogenic | CFTR-related disorder | 2018-03-09 | criteria provided, single submitter | curation | |
| Baylor Genetics | RCV000047162 | SCV001163477 | likely pathogenic | Cystic fibrosis | criteria provided, single submitter | clinical testing | ||
| ARUP Laboratories, |
RCV000507054 | SCV001159395 | uncertain significance | not provided | 2024-11-11 | criteria provided, single submitter | clinical testing | The CFTR c.489+3A>G variant (rs377729736, ClinVar Variation ID: 53971), also known as 621+3A>G, is reported in the literature in individuals affected with cystic fibrosis, congenital bilateral absence of vas deferens (CBAVD), and sarcoidosis, including individuals with a severe pathogenic variant on the opposite chromosome (Amato 2012, Angyal 2024, Gallati 2009, Giuliani 2010, Sermet-Gaudelus 2010, Soltysova 2018, Tzetis 2001). However, this variant has also been reported in an asymptomatic individual who carries a pathogenic nonsense variant in trans (Forzan 2010), and in cis with a truncating variant in an individual with cystic fibrosis (Loumi 2008). This variant is found in the general population with an overall allele frequency of 0.023% (63/276,630 alleles) in the Genome Aggregation Database (v2.1.1). Computational analyses (Alamut v.2.11) predict that this variant may impact splicing by weakening the nearby canonical donor splice site. Functional studies show aberrant mRNA splicing making up about 35% of transcripts, but it is unknown if this level altered transcripts is sufficient to cause disease (Forzan 2010, Tzetis 2001). Due to conflicting information, the clinical significance of the c.489+3A>G variant is uncertain at this time. References: Amato F et al. Extensive molecular analysis of patients bearing CFTR-related disorders. J Mol Diagn. 2012 Jan;14(1):81-9. PMID: 22020151. Angyal D et al. CFTR function is impaired in a subset of patients with pancreatitis carrying rare CFTR variants. Pancreatology. 2024 May;24(3):394-403. PMID: 38493004. Forzan M et al. Is CFTR 621+3 A>G a cystic fibrosis causing mutation? J Hum Genet. 2010 Jan;55(1):23-6. PMID: 19893581. Gallati S et al. Cystic fibrosis transmembrane conductance regulator mutations in azoospermic and oligospermic men and their partners. Reprod Biomed Online. 2009 Nov;19(5):685-94. PMID: 20021716. Giuliani R et al. Identification of the second CFTR mutation in patients with congenital bilateral absence of vas deferens undergoing ART protocols. Asian J Androl. 2010 Nov;12(6):819-26. PMID: 20657600. Loumi O et al. CFTR mutations in the Algerian population. J Cyst Fibros. 2008 Jan;7(1):54-9. Epub 2007 Jun 14. PMID: 17572159. Sermet-Gaudelus I et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Thorax. 2010 Jun;65(6):539-44. PMID: 20522854. Soltysova A et al. Comprehensive genetic study of cystic fibrosis in Slovak patients in 25 years of genetic diagnostics. Clin Respir J. 2018 Mar;12(3):1197-1206. PMID: 28544683. Tzetis M et al. Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621+3A-->G, 2751+2T-->A, 296+1G-->C, 1717-9T-->C-D565G) and one nonsense mutation (E822X) in the CFTR gene. Hum Genet. 2001 Dec;109(6):592-601. PMID: 11810271. |
| Mendelics | RCV000047162 | SCV000886393 | uncertain significance | Cystic fibrosis | 2018-11-05 | criteria provided, single submitter | clinical testing | |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000047162 | SCV000697029 | likely pathogenic | Cystic fibrosis | 2024-06-26 | criteria provided, single submitter | clinical testing | Variant summary: CFTR c.489+3A>G, legacy name c.621+3A>G, alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 in silico tools via Alamut predict that the variant abolishes or weakens the canonical 5' splicing donor site. This is further supported by experimental evidence reporting an impact on mRNA splicing as corroborated by two independent studies that showed a reproducible distribution of transcripts resulting from activation of an alternate splice site (approx 28.3%) and transcripts resulting from complete skipping of exon 4 (approx 6.8%) in addition to levels of wild-type transcripts (approx remaining 65%) (Tzetis_2001, Forzan_2010). Furthermore, the pattern of abnormal splicing demonstrated by this variant is very similar to that of c.489+1G>T (legacy name c.621+1G>T) considered to be a well-recognized pathogenic CFTR variant (Tzetis_2001). The variant allele was found at a frequency of 0.00025 in 247812 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in CFTR causing Non-Classic Cystic Fibrosis (0.00025 vs 0.013), allowing no conclusion about variant significance. c.489+3A>G has been reported in the literature in individuals affected with Cystic Fibrosis or with a provisional CF diagnosis with intermediate sweat chloride levels (e.g. Tzetis_2001, Kanavakis_2003, Soltysova_2018, Claustres_2017, Angyal_2024) and in individuals with other CFTR-related diseases such as CBAVD (e.g. Amato_2012), azoospermia (e.g. Gallati_2009), sarcoidosis (Bombieri_2000), and chronic pancreatitis (Sofia_2016). These data, when ascertained conservatively, limited to patients with a confirmed diagnosis of CF, support the notion that the variant is likely to be associated with disease. At least one report of an asymptomatic 8 year old girl harboring this variant in trans with another pathogenic CFTR variant (p.Q552*) has been ascertained (Forzan_2010). This patient had inconsistent sweat chloride levels ranging from 49-75 mEq/L in three independent measurements and the possibility of subclinical disease cannot be entirely ruled out. In addition, the variant was also reported to have been observed in cis with c.4332delTG (legacy name) in a CF patient harboring c.2183AA/G (legacy name) on the other allele (Loumi_2008). However, to our knowledge, there are no additional reports of this co-occurrence to substantiate this finding. The following publications have been ascertained in the context of this evaluation (PMID: 26990548, 22020151, 22439019, 10980579, 28603918, 25304080, 25308578, 19893581, 20021716, 17850636, 20657600, 20932301, 12752573, 17572159, 27264265, 28544683, 11810271). The CFTR2 database states this variant to have varying consequences. ClinVar contains an entry for this variant (Variation ID: 53971). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
| Gene |
RCV000507054 | SCV000617530 | uncertain significance | not provided | 2017-07-28 | criteria provided, single submitter | clinical testing | The c.489+3A>G variant in the CFTR gene, also referred to as c.621+3A>G, has been reported in the heterozygous state patients with sarcoidosis, CAVD, and azoospermia without CAVD (Bombieri et al., 2000; Amato et al., 2012; Gallati et al., 2009). This variant reduces the quality of the splice donor site in intron 4, and may cause abnormal gene splicing. The c.489+3A>G variant is observed in 30/50716 (0.06%) alleles in the ExAC dataset (Lek et al., 2016). We interpret c.489+3A>G as a variant of uncertain significance. |
| Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000507054 | SCV000601124 | likely pathogenic | not provided | 2023-07-05 | criteria provided, single submitter | clinical testing | The CFTR c.489+3A>G variant has been reported in the published literature in individuals with cystic fibrosis (CF) who carried a CFTR pathogenic variant on the opposite chromosome (PMID: 11810271 (2001)). It has also been observed in individuals with sarcoidosis (PMID: 10980579 (2000)), azoospermia (PMID: 20021716 (2009)), bronchiectasis (PMID: 33260873 (2020)), and congenital bilateral absence of the vas deferens (CBAVD) (PMID: 22020151 (2012)). However, it has also been observed in an asymptomatic individual who carried a CFTR pathogenic variant on the opposite chromosome (PMID: 1989381 (2010)). RNA studies have shown that it causes the synthesis of aberrantly spliced CFTR mRNA transcripts, but it does not prevent the synthesis of normally spliced CFTR mRNA (PMID: 11810271 (2001), 19893581 (2010)). The frequency of this variant in the general population, 0.0021 (23/11152 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant may affect proper CFTR mRNA splicing. Based on the available information, this variant is classified as likely pathogenic. |
| Eurofins Ntd Llc |
RCV000507054 | SCV000344240 | uncertain significance | not provided | 2017-11-22 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000047162 | SCV000075175 | pathogenic | Cystic fibrosis | 2025-01-21 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 4 of the CFTR gene. It does not directly change the encoded amino acid sequence of the CFTR protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs377729736, gnomAD 0.04%). This variant has been observed in individual(s) with cystic fibrosis, sarcoidosis, azoospermia, or congenital absence of the vas deference (PMID: 10980579, 11810271, 19893581, 20021716, 22020151). This variant is also known as 621+3A>G. ClinVar contains an entry for this variant (Variation ID: 53971). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of 4, but is expected to preserve the integrity of the reading-frame (PMID: 11810271). For these reasons, this variant has been classified as Pathogenic. |
| Prevention |
RCV001009491 | SCV004110708 | likely pathogenic | CFTR-related disorder | 2024-03-05 | no assertion criteria provided | clinical testing | The CFTR c.489+3A>G variant is predicted to interfere with splicing. This variant has been reported in patients with cystic fibrosis, congenital bilateral absence of vas deferens (CBAVD), azoospermia, or sarcoidosis, including in patients with a pathogenic variant on the opposite chromosome (Amato et al. 2011. PubMed ID: 22020151; Bombieri et al. 2000. PubMed ID: 10980579; Gallati et al. 2009. PubMed ID: 20021716; Giuliani et al. 2010. PubMed ID: 20657600; Kanavakis et al. 2003. PubMed ID: 12752573; Sermet-Gaudelus et al. 2010. PubMed ID: 20522854; Soltysova et al. 2017. PubMed ID: 28544683; Tzetis et al. 2001. PubMed ID: 11810271). This variant was also reported in trans with a second pathogenic variant in an asymptomatic female child; however, her sweat chloride testing suggested possible subclinical disease (49-75 mEq/L) (Forzan et al. 2009. PubMed ID: 19893581). Additionally, functional studies demonstrate that this variant leads to aberrant splicing with a defect consistent with other known splicing variants at this location (c.489+1G>T aka 621+1G>T; Tzetis et al. 2001. PubMed ID: 11810271; Forzan et al. 2009. PubMed ID: 19893581). This variant is reported in 0.039% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Taken together, this variant is interpreted as likely pathogenic. |
| Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000507054 | SCV001980455 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000507054 | SCV001979366 | uncertain significance | not provided | no assertion criteria provided | clinical testing |